MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Accuray’s CyberKnife goes head-to-head against Intuitive’s da Vinci robot

Accuray’s CyberKnife goes head-to-head against Intuitive’s da Vinci robot

By

Accuray logo

Sunnyvale, Calif.-based Accuray (NSDQ:ARAY) aims to establish a new gold standard for treating early-stage prostate cancer, with a 1st-of-its-kind clinical trial pitting its CyberKnife radiosurgery device against competing therapies, including Intuitive Surgical’s (NSDQ:ISRG) da Vinci surgical robot.

"An increasing number of patients are attracted to treatment with the CyberKnife System due to its unique ability to precisely treat the prostate while avoiding surrounding healthy tissue and critical structures," president & CEO Euan Thomson said in prepared remarks.

"Accuray believes in taking the lead in supporting studies, such as the Pace study, that will generate clinical data to support the benefits of technical innovation and provide the highest level of comparative evidence for the benefit of prostate cancer patients worldwide," Thomson added.

Accuray’s new Prostate Advances in Comparative Evidence study plans to follow more than 1,000 patients across 30 to 40 centers globally for up to 5 years after treatment.

Patients will receive either treatment with the CyberKnife system, surgical prostatectomy with the da Vinci robot, manual laparoscopic prostatectomy or conventionally fractionated intensity modulated radiation therapy.

Researchers will measure erectile function preservation, urinary and rectal toxicity, urinary incontinence and other common post-treatment side effects, according to a press release.

The news follows a new study finding that robot-assisted radical prostatectomy has cornered the market on treatment for localized prostate cancer.

"Contemporary data from the United States demonstrate that robot-assisted radical prostatectomy has supplanted open radical prostatectomy as the most common surgical approach for prostate cancer," according to the study’s authors. "Adjusted analyses demonstrate superior perioperative outcomes after robot-assisted radical prostatectomy in virtually all of the examined outcomes," when compared with open radical prostatectomy.

The CyberKnife radiosurgery system uses precisely targeted, massive doses of X-ray radiation to non-invasively destroy tumors.*

ARAY shares took a hit today, trading 3% lower to $7.67 as of about 12:15 p.m. today.

Correction, April 27, 11:00 a.m.: This article mistakenly stated that Accuray acquired the CyberKnife technology through the acquisition of TomoTherapy. The CyberKnife system was originally Accuray’s technology.

In case you missed it

RSS From Medical Design & Outsourcing

  • These medtech companies care a lot about research
    They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report… […]
  • Traco Power launches new AC/DC power supplies
    Traco Power (Baar, Switzerland) announced its newest high efficiency, miniaturized ac/dc power supplies: the TPP 180 series for medical and industrial and TPI 180 for industrial. The power supplies measure only 2-by-3-by-1.24 inches in the open frame version — with global safety approvals for medical or industrial markets. They come in16 standard models with single… […]
  • NIH launches $9.8M neuromodulation competition
    The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous… […]
  • Junkosha boosts production of PTFE liners and FEP-based heat shrink
    Junkosha announced today that it plans to double production capacity to meet shortages of PTFE liners and FEP-based heat shrink for catheter manufacturers. Both OEMs and contract manufacturers in the catheter space are stressed from shortages in the global supply of vital components, according to the Japanese maker of sophisticated fluoropolymer application technologies. “We believe this… […]
  • Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
    With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As the new year gets underway, expectations for the… […]
  • Former Zimmer Biomet executive has a new job
    Carrie Nichol, the former chief accounting officer of Zimmer Biomet (NYSE:ZBH), has a new job outside of the medtech industry. Nichol, who also served as vice president, controller and principal accounting officer at Zimmer Biomet, is now a VP and controller at Minnetonka, Minnesota-based Cargill. Her departure was among the many notable medtech executive moves… […]
  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]

Leave a Reply